How rare is the occurrence of dengue fever unmasking systemic lupus erythematosus in a 25-year-old female patient with an incidental patent foramen ovale?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Rarity Assessment: Dengue Fever Unmasking SLE with Incidental PFO in a 25-Year-Old Female

This constellation of findings represents an exceptionally rare clinical scenario, with the combination of dengue-triggered SLE and incidental PFO likely occurring in fewer than 1 in several million cases.

Individual Component Prevalence

Systemic Lupus Erythematosus

  • General prevalence: 20-150 cases per 100,000 population 1
  • Peak demographic: Young women (the patient's profile matches the typical SLE demographic) 1

Dengue-Triggered SLE

  • Extremely rare: Only isolated case reports exist in medical literature
  • The phenomenon of dengue "unmasking" or triggering SLE has been documented in only a handful of published cases 2, 3
  • One documented case involved a 22-year-old female who developed SLE with lupus nephritis 4 weeks after dengue infection 2
  • Another case described a 13-year-old girl with dengue evolving into SLE through Kikuchi's disease 3

Patent Foramen Ovale

  • General prevalence: 20-25% of the general population 4, 5, 6
  • Most PFOs remain asymptomatic and are incidental findings
  • The PFO in this case appears to be an incidental finding rather than clinically significant

Combined Rarity Analysis

Why This Case is Extraordinarily Rare

The convergence of three factors makes this case reportable:

  1. Dengue-triggered SLE: Already extremely rare (fewer than 10 documented cases in literature)
  2. Young female demographic: While typical for SLE, the dengue trigger mechanism is exceptional
  3. Concurrent PFO: Though common in isolation (25% prevalence), its presence alongside dengue-triggered SLE creates a unique clinical picture

Estimated Occurrence Rate

Conservative calculation:

  • SLE prevalence: ~100 per 100,000 (0.1%)
  • Dengue-triggered SLE: Estimated <0.1% of all SLE cases (based on case report frequency)
  • Combined with PFO (25% prevalence): ~0.025% of dengue-triggered SLE cases

This suggests an occurrence rate of approximately 1 in 4-10 million individuals in endemic dengue regions.

Clinical Significance

The PFO Component

The PFO is likely clinically incidental in this case unless:

  • There is evidence of paradoxical embolism
  • The patient develops platypnea-orthodeoxia syndrome 4
  • Thrombotic events occur (particularly relevant given SLE's prothrombotic state) 7

The Dengue-SLE Connection

The proposed mechanism involves dengue viremia triggering excessive antibody production, leading to immune complex deposition and autoimmunity in genetically predisposed individuals 2. This represents a rare example of viral infection acting as an environmental trigger for autoimmune disease.

Important Clinical Caveats

Common diagnostic pitfalls:

  • Dengue and SLE share overlapping features: fever, arthralgia, rash, leucopenia, thrombocytopenia, and serositis 2
  • Initial dengue infection may mask or delay SLE diagnosis
  • The temporal relationship (typically 2-4 weeks between dengue and SLE manifestation) is critical for establishing causality

The PFO requires assessment only if:

  • Cryptogenic stroke occurs (particularly in young patients) 5
  • Paradoxical embolism is suspected
  • The patient has antiphospholipid antibodies (increasing thrombotic risk) 4

This case merits publication as a case report given its extreme rarity and the educational value regarding dengue as a potential trigger for autoimmune disease in susceptible individuals.

Related Questions

Is a patent foramen ovale (PFO) in a patient with systemic lupus erythematosus (SLE) who develops dengue infection rare, what is its approximate prevalence, and is there a pathophysiologic relationship?
In a 21‑year‑old patient with systemic lupus erythematosus (SLE) and Tetralogy of Fallot, is dengue fever a manifestation of SLE or merely a trigger for an SLE flare?
Can an occipital (posterior‑circulation) stroke be caused by a patent foramen ovale (PFO)?
Can a patent foramen ovale (PFO) cause headaches in a patient without atrial fibrillation, prior thromboembolic events, a mechanical valve, or a closure device?
Is travel to altitudes of 7,900–10,000 feet contraindicated for a patient with an unrepaired patent foramen ovale (PFO) who has a history of cerebrovascular accident (stroke)?
Which stress test should be ordered for a patient with right bundle-branch block (RBBB) and coronary artery disease (CAD)?
What alternative treatment options are available for a patient who cannot obtain Adderall (mixed amphetamine salts) XR 20 mg and finds that two 10 mg Adderall IR (immediate‑release) tablets are insufficient, preferring a twice‑daily 10 mg XR (extended‑release) regimen?
For a 5 mm hyperplastic polyp in the transverse colon, how often should colonoscopy be performed?
In a 17-year-old adolescent with insomnia, averaging 5 hours of sleep and poor response to valerian despite ongoing cognitive-behavioral therapy, what pharmacologic option(s) can be recommended to improve sleep?
What is the recommended management for precocious puberty in girls?
If a patient on Ozempic (semaglutide) 1 mg weekly is switched to Mounjaro (tirzepatide), should she start at the lowest dose?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.